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Abstract
Background: Methamphetamine is one of the fastest growing illicit drugs worldwide, causing multiple organ damage and
excessive natural deaths. The authors aimed to identify potential laboratory indices and clinical characteristics associated
with natural death through a two-phase study.
Methods: Methamphetamine-dependent patients (n=1,254) admitted to a psychiatric center in Taiwan between 1990 and
2007 were linked with a national mortality database for causes of death. Forty-eight subjects died of natural causes, and
were defined as the case subjects. A time-efficient sex- and age-matched nested case-control study derived from the cohort
was conducted first to explore the potential factors associated with natural death through a time-consuming standardized
review of medical records. Then the identified potential factors were evaluated in the whole cohort to validate the findings.
Results: In phase I, several potential factors associated with natural death were identified, including aspartate
aminotransferase (AST), alanine aminotransferase (ALT), comorbid alcohol use disorder, and the prescription of
antipsychotic drugs. In phase II, these factors were confirmed in the whole cohort using survival analysis. For the
characteristics at the latest hospital admission, Cox proportional hazards models showed that the adjusted hazard ratios for
natural death were 6.75 (p,0.001) in the group with markedly elevated AST (.80 U/L) and 2.66 (p,0.05) in the group with
mildly elevated AST (40–80 U/L), with reference to the control group (,40 U/L). As for ALT, the adjusted hazard ratios were
5.41 (p,0.001), and 1.44 (p.0.05). Comorbid alcohol use disorder was associated with an increased risk of natural death,
whereas administration of antipsychotic drugs was not associated with lowered risk.
Conclusions: This study highlights the necessity of intensive follow-up for those with elevated AST and ALT levels and
comorbid alcohol use disorder for preventing excessive natural deaths.
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Introduction
The use of methamphetamine has become one of the fastest
growing illicit drug problems worldwide since 1990s, particular in
South-east Asia, Australia, and North America [1]. Methamphet-
amine is now spreading easily, supplied by makeshift-scale
(‘kitchen’ and ‘living room’) and industrial-scale clandestine
laboratories, where it is often produced using legally purchased
ingredients [2]. Furthermore, psychiatric or medical staff members
were more likely to care for patients with methamphetamine-
related problems in the past decade, and there is emerging
literature on the damages associated with regular methamphet-
amine use, including physical and mental health problems [3], and
premature death [4,5,6]. As a basis for prevention efforts,
however, studies on the factors associated with natural death in
this population are limited.
Natural death can result from the comorbid illnesses (e.g.,
alcoholism, hepatitis virus types B and C) that methamphetamine
users are likely to have [3,7], or from the harmful effects directly
attributable to methamphetamine [3,8]. Regarding the latter,
cardiovascular pathology is a well-known toxic effect of metham-
phetamine, and potential complications include tachycardia,
arrhythmia, increased blood pressure, myocardial infarction, and
even sudden cardiac death [8]. Additionally, methamphetamine
use can induce complications in several major organ systems,
including the central nervous system, kidneys, hepatic system, and
musculature [3]. To monitor the damage to these organ systems in
patients with methamphetamine dependence, routine laboratory
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reflecting the functions of multiple organs (e.g., aspartate
aminotransferase for heart, muscle, and liver) or single specific
organs (e.g., thyroxine for thyroid function) [9]. We hypothesized
that laboratory indices related to organ systems damage could be
proxies in association with natural death.
For exploring the laboratory indices and other clinical
characteristics (e.g., comorbid illnesses, prescribed psychiatric
drugs) in association with methamphetamine-related natural
death, we conducted a two-phase study using a cohort with
methamphetamine dependence monitored for a long-term period.
Due to unavailability of risk factors for natural death in prior
studies, we first conducted a time-efficient nested case-control
study derived from the cohort to explore the potential factors
associated with natural death. We then evaluated the identified
potential factors in the whole cohort to validate the findings. The
study aimed to identify potential laboratory indices as surrogate
markers for natural death, along with the clinical characteristics
associated with natural death.
Methods
Setting and Patients
The source of subjects was the Taipei City Psychiatric Center, a
psychiatric service center designated for northern Taiwan. The
methodology used is described extensively elsewhere and was used
in research on suicide mortality among methamphetamine
dependents [4]. Briefly, an initial series of 1,548 patients with
methamphetamine-related problems admitted to the psychiatric
center from January 1, 1990 to December 31, 2007 were
retrospectively enrolled. Following the practice of previous studies
[4,10], we then applied strict inclusion criteria based on the
principal psychiatric diagnosis of methamphetamine dependence
according to the Diagnostic and Statistical Manual of Mental
Disorders, Third Edition Revised (DSM-III-R) and Fourth Edition
(DSM-IV), which excluded opportunistic users who had used
methamphetamine less than 20 times in the past year. The use
pattern of methamphetamine for each subject was obtained
through careful clinical, semi-structured interviews conducted by a
resident psychiatrist and a board-certificated psychiatrist during
hospitalization. Comorbidity of alcohol or other substance use
disorders for each subject was pertinent to the patients’ clinical
treatment and carefully diagnosed by the psychiatrists.
Furthermore, to investigate the effect from methamphetamine
without being confounded by other substances, we excluded any
patient whose principal diagnosis of methamphetamine depen-
dence was changed to another substance use disorder(s) after the
index admission. Finally, 1,254 methamphetamine-dependent
subjects were enrolled as the cohort.
By using a national identity number as the subject identifier, the
cohort was electronically linked with data files held in the Taiwan
Department of Health Death Certification System between
January 1, 1990 and December 31, 2007, and 130 deaths were
identified. The linkage process was approved by the Department
of Health in Taiwan [11]. Of the deceased, 48 patients who died
natural deaths were selected as the case subjects. The remainder
(n=82) died from unnatural causes.
Phase I: Nested case-control study
We first conducted a nested case-control study derived from the
defined cohort (N=1,254) to explore the potential risk factors
associated with methamphetamine dependence and natural death
by means of a time-consuming and comprehensive chart review
process.Basedonrisk-setsampling,eachcasewasmatchedwithfour
controls or fewer if four suitable controls could not be identified.
Matched for age (65 years), sex, and the year of index admission,
controls were selected randomly from the cohort subjects who were
alive at the time of death of the case subject. Index admission was
defined as the earliest hospitalization during the study period.
Among the 1254 subjects, 358 had multiple hospitalizations, but the
proportion did not differ between cases with natural death and
others. No suitable control was found for three cases, so that a total
of 45 case-controlled pairs (i.e., 45 cases and 167 controls, n=212)
were included in the study. Of the pairs, four controls were used in
each case of 36 pairs, three controls in each case of six pairs, two
controls in each case of two pairs, and one control in one pair.
Semi-structured case notes [12] were systematically recorded for
any patient who was admitted to the source hospital and included
information on demographic characteristics and psychiatric
history, details of the patient’s mental status, physical condition,
alcohol/drug use disorders, and family history. A parallel
interview to confirm the information with family members or
others who knew the patient well was routinely conducted during
the admission. Psychiatric drugs (e.g., antipsychotic drugs, mood
stabilizers, and antidepressants) were prescribed when clinically
indicated. On the first morning after admission, a fasting venous
blood sample was routinely drawn for biochemical analyses.
Information for each subject was carefully checked using a
combined standardized review process by two trained clinical
psychologists and then double-checked by a senior psychiatrist
(CJK). All of the chart reviewers were blinded as to the subjects’
case or control status. In order to facilitate the chart review, a
structured abstraction form containing 125 items was developed
that typically required at least 1 hour to complete, including
information relating to the index and latest hospital admissions
during the study period on demographics, social support network,
substance use history, symptom profile, prescription of psychiatric
drugs, and laboratory data.
Before the review process, all of the chart reviewers participated
in a reliability study and rated information independently for four
cases and eight controls. The results showed satisfactory inter-rater
reliability, with the kappa values of key variables all greater than
0.7, including symptom profiles and comorbid alcohol use
disorders.
For statistical analyses, group comparisons between cases and
controls were performed using univariate conditional logistic
regression analyses initially, and then the variables with a
reasonable association with natural death (p,0.05) were entered
into the multivariable regression analyses.
Phase II: Cohort study
For those variables identified as factors associated with the risk
of natural death from phase I study (reported later), the
information was then retrieved for those subjects not included in
the nested case-control study. Data collection took about
10 minutes for each subject by means of a brief chart review
process. The whole cohort was then analyzed using Cox
proportional hazards analyses to validate the results and precisely
estimate the risks of natural death based on the identified risk
factors.
All of the multivariable models were conducted using SAS
software, version 9.2 (SAS Institutes Inc., Cary, NC, USA). A p
value of 0.05 was considered significant in the multivariable
regression analyses.
Ethics Statement
This study was approved by the Institutional Review Board of
the Committee on Human Subjects of Taipei City Hospital. The
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process in the fully-restricted medical records room. A waiver was
granted for informed consent due to the minimal risk to the
privacy of individual subjects and that the identities of subjects
were fully encrypted to preserve anonymity during the statistical
analysis.
Results
Demographics and Drug Use History
Both the deceased patients and the controls among the
methamphetamine dependents in this study had similar distribu-
tions of age at first methamphetamine use, marital status, living
with family, educational level, employment, and socio-economic
status based on Hollingshead’s classification [13] (Table 1).
Among the 48 methamphetamine dependent patients who died
from natural causes, the mean interval from the index admission to
death was 5.3 (SD=4.0) years. The causes of death included
cardiovascular (n=12), respiratory (n=3), hepatic (n=8), cere-
brovascular (n=2), neoplasm (n=4), endocrine and metabolic
(n=3), genitourinary (n=1), neurological (n=1), shock without
mention of trauma (n=1), sudden death with unknown cause
(n=1; ICD-9 code: 798), and other unknown and unspecified
causes (n=12; ICD-9 code: 799.9).
Clinical Characteristics at the Index and Latest
Admissions
The clinical characteristics at the index and latest admissions
were compared between cases and controls in Table 2. Among the
comorbidities examined, a greater proportion of the deceased
patients had alcohol use disorders than did the controls. Among the
laboratory markers listed in the table, deceased patients had
significantly higher mean levels of AST and ALT. The findings in
the latest admission were similar. A higher proportion of case
patients had alcohol use disorders at the latest admission than did
the controls, and also greater AST and ALT levels as well.
Additionally, the case patients were less likely to receive antipsy-
chotic drugs at the latest admission than controls (46.7% vs. 67.5%,
p=0.009) (Table 2). There was no difference between cases and
controls in terms of other laboratory indices, including electrolytes
(sodium, potassium, chloride), fasting glucose, renal function (blood
urea nitrogen, creatinine), uric acid, albumin, globulin, total
protein, thyroxine, or platelet count (data not shown).
The proportions of underlying physical illnesses requiring
clinical attention in case and control subjects at the index
admission were 6.7% (3/45) vs. 3.0% (5/162) (p=0.251) for
cardiovascular disease, 6.7% (3/45) vs. 1.2% (2/162) (p=0.065)
for endocrine disease, 15.6% (7/45) vs. 6.0% (10/167) (p=0.074)
for gastrointestinal disease, 6.7% (3/45) vs. 5.4% (9/162)
(p=0.721) for genitourinary disease, 4.4% (2/45) vs. 2.4% (4/
162) for hematological disease, and 13.3% (6/35) vs. 6.0% (10/
167) (p=0.181) for hepatic disease. There were no statistical
differences between two groups.
Regarding family history of psychiatric disorders (including
schizophrenia, substance use disorders, and suicide), no difference
between case and control subjects was found (data not shown).
To conduct the multivariable analyses, we used the variables at
the latest admission due to the inclusion of more variables with
statistical significance than at the index admission, along with
shorter periods between the baseline and the censored point,
which improved predictive power.
Multivariable Analyses
Multivariable conditional logistic regression analyses comprised
the variables with significant associations (p,0.05), including AST,
ALT, antipsychotic drug use, and comorbid alcohol use disorder.
Multivariable analyses were analyzed based on AST and ALT
separately due to high correlation between AST and ALT
(Pearson correlation coefficient r=.89, p,0.001) and strong
associations of both markers and natural death in the unadjusted
analyses.
Additionally, previously published literature [9] revealed that
AST and ALT levels were highly associated with hepatitis B, and
with alcohol use disorders as well. Therefore, hepatitis B surface
antigen and alcohol use disorders were required as the covariates
in the final multivariable models. For easier-to-interpret findings
and clinical application, we categorized AST and ALT levels into
three subgroups (,40 U/L: normal, 40–80 U/L: mildly elevated,
Table 1. Socio-demographic characteristics of natural death and living controls (1:4 ratio) among patients with methamphetamine
dependence at the index admission.
Characteristic
Deceased
patients
(N=45)
Living controls
(N=167)
Unadjusted odds
ratio
95% confidence
interval
n( % ) n( % )
Male 41 (91.1) 151 (90.4) * *
Being married 11 (24.4) 33 (19.8) 1.27 0.55–2.91
Living with family 38 (86.4) 144 (87.8) 0.77 0.26–2.25
Education $12 years 14 (31.1) 70 (42.2) 0.63 0.31–1.25
Employment (past 1 year) 23 (51.1) 95 (56.9) 0.77 0.38–1.55
Hollingshead socio-economic class IV or V (past 1 year) 40 (88.9) 144 (87.3) 1.15 0.41–3.22
Mean (SD) Mean (SD)
Age (years) at index admission, mean (SD) 30.7 (7.8) 29.4 (7.9) 1.06 0.97–1.15
Age at first methamphetamine use (years), mean (SD) 24.0 (8.3) 24.7 (6.9) 0.97 0.88–1.07
Duration of methamphetamine use (years), mean (SD) 5.4 (4.0) 4.7 (3.5) 1.04 0.94–1.15
*Matched by design.
doi:10.1371/journal.pone.0029325.t001
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The normal upper limit of each marker was set as 40 U/L.
As shown in Table 3, mildly elevated AST increased the risk of
natural death (odds ratio=4.37, p,0.01) relative to normal AST
levels; the risk was even higher when AST was markedly elevated
(odds ratio=53.35, p,0.001). Mildly and markedly elevated ALT
levels also raised the risks of natural death (odds ratio=5.11,
p,0.05; odds ratio=7.65, p,0.001). Additionally, in both of
models, comorbid alcohol use disorder was associated with an
increased risk of natural deaths, whereas prescription of antipsy-
chotic drugs lowered the risk.
Cohort study
For validating the associations between AST and ALT and
natural deaths, we conducted a further study in the whole cohort
(N=1254) by means of Cox proportional hazards analyses
(Table 4). After adjusting for covariates, mildly elevated AST
increased the risk of natural death (adjusted hazard ratio=2.66,
p,0.05) relative to normal AST levels; the risk was even higher
when AST was markedly elevated (adjusted hazard ratio=6.75,
p,0.001). These results are similar to the findings from the phase I
study.
As for the ALT model, only markedly elevated ALT levels
raised the risks of natural death (adjusted hazard ratio=5.41,
p,0.001). In both models, comorbid alcohol use disorder was
associated with an increased risk of natural death. Although the
prescription of antipsychotic drugs tended to lower this risk, the
reduction did not reach statistical significance.
The distribution of AST and ALT levels in the cases of natural-
death and the remaining non-cases of the original cohort,
Table 2. Clinical characteristics of patients with methamphetamine dependence dying from natural causes and living controls
with methamphetamine dependence at the index admission and the latest admission using univariate conditional logistic
regression.
Characteristic
Deceased patients
(N=45)
Living controls
(N=167)
Unadjusted Odds
ratio
95% confidence
interval
Index admission n( % ) n( % )
With psychosis 32 (71.1) 115 (68.9) 1.16 0.54–2.49
Co-morbidity
Alcohol use disorders 9 (20.0) 11 (6.6) 3.63** 1.37–9.58
Other substance disorders 12 (26.7) 29 (17.4) 1.76 0.77–4.01
Schizophrenia 4 (8.9) 23 (13.8) 0.61 0.20–1.88
Psychosis-related symptoms 30 (66.7) 125 (74.9) 0.68 0.33–1.41
Auditory hallucination 23 (51.1) 100 (59.9) 0.69 0.36–1.35
Visual hallucination 13 (28.9) 37 (22.2) 1.40 0.68–2.90
Persecutory delusion 19 (42.2) 82 (49.1) 0.78 0.38–1.60
Reference delusion 16 (35.6) 54 (32.3) 1.19 0.58–2.44
Discharged against medical advice 14 (31.1) 62 (37.1) 0.80 0.40–1.60
Antidepressant use 11 (24.4) 26 (15.6) 1.68 0.73–3.88
Benzodiazepine use 33 (73.3) 114 (68.7) 1.23 0.58–2.60
Mood stabilizer 0 (0.0) 5 (3.0) 0.00 0.00–
Antipsychotic drug use 22 (48.9) 101 (60.5) 0.60 0.29–1.22
Laboratory markers Mean (SD) Mean (SD)
Blood hemoglobin (g/dL) 14.9 (4.4) 14.7 (1.7) 1.03 0.91–1.16
Leukocytes (10
3*m/L) 6.9 (2.9) 7.4 (2.1) 1.00 1.00–1.00
Serum AST (U/L) 84.9 (134.7) 29.2 (25.8) 1.02*** 1.01–1.03
Serum ALT (U/L) 88.2 (143.6) 34.7 (55.1) 1.01** 1.00–1.01
Serum cholesterol (mg/dL) 172.1 (41.6) 179.3 (45.2) 1.00 0.99–1.01
Serum triglyceride (mg/dL) 119.8 (67.7) 124.3 (84.7) 1.00 0.99–1.01
Hepatitis B surface antigen, n (%) 10 (23.3) 28 (19.0) 1.23 0.55–2.72
Latest admission
a
Alcohol use disorders, n (%) 11 (24.4) 21 (12.6) 2.38* 1.02–5.55
Antipsychotic drug use, n (%) 21 (46.7) 112 (67.5) 0.38** 0.18–0.78
Serum AST (U/L), mean (SD) 87.4 (136.2) 29.0 (29.9) 1.03*** 1.01–1.05
Serum ALT (U/L), mean (SD) 91.9 (143.4) 31.9 (44.0) 1.02*** 1.01–1.03
Hepatitis B surface antigen, n (%) 10 (24.4) 29 (19.9) 1.19 0.53–2.67
aOnly variables at latest admission with p,0.05 based on univariate conditional logistic regression and hepatitis B surface antigen are included.
*p,0.05,
**p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0029325.t002
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proportions of both markedly and mildly elevated levels than the
remaining cohort subjects.
Subjects without alcoholism
Since comorbid alcoholism was significantly associated with
natural death, we then restricted the subjects to the patients
without comorbid alcoholism (35 cases with natural death and
1105 subjects without natural death) and conducted further
analysis based on the model AST, which revealed similar results.
The adjusted hazard ratios for those with mildly and markedly
elevated AST levels were 3.19 (95% CI, 1.37–7.41, p=0.007) and
5.20 (95% CI, 1.72–15.74, p=0.004), respectively, without
changing direction compared to the model AST listed in Table 4.
Table 3. Multivariable conditional logistic regression of the factors at the latest admission associated with natural death based on
AST and ALT respectively (45 deceased patients, 167 living controls).
AST ALT
Adjusted odds ratio
95% confidence
interval
Adjusted odds
ratio
95% confidence
interval
Enzyme (U/L)
Normal (,40) Reference Reference
Mildly elevated (40–80) 4.37** 1.47–12.99 5.11* 1.32–19.80
Markedly elevated (.80) 53.35*** 5.05–564.19 7.65*** 2.53–23.12
Alcohol use disorders 1.76 0.45–6.82 2.38 0.68–8.33
Presence of hepatitis B surface antigen 0.86 0.32–2.32 1.00 0.40–2.53
Use of antipsychotic drugs (presence/absence) 0.34* 0.13–0.91 0.26** 0.10–0.68
*p,0.05,
**p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0029325.t003
Table 4. Cox proportional hazards regression of risk factors at the latest admission for natural death based on AST and ALT
(N=1,254).
Characteristic Unadjusted Adjusted
a
N( % )
Natural death,
n (%) Hazard ratio
95% confidence
interval Hazard ratio
95% confidence
interval
Model AST (based on AST)
AST
+
Normal (,40) 838 (78.5) 21 (48.8) 1.00 – 1.00 –
Mild elevated (40–80) 160 (15.0) 11 (25.6) 3.37** 1.62–7.00 2.66* 1.21–5.82
Marked elevated (.80) 69 (6.5) 11 (25.6) 8.72*** 4.17–18.25 6.75*** 3.02–15.11
Alcohol use disorder (yes/no) 114 (9.1) 13 (27.1) 5.42*** 2.84–10.34 3.46** 1.64–7.31
Antipsychotic drug use (yes/no) 743 (59.3) 21 (43.8) 0.58 0.33–1.03 0.70 0.37–1.31
HBsAg (yes/no)
+++ 180 (18.3) 11 (26.2) 1.48 0.74–2.95 1.23 0.60–2.53
Model ALT
ALT
++
Normal (,40) 814 (76.8) 23 (52.3) 1.00 – 1.00 –
Mild elevated (40–80) 153 (14.4) 8 (18.2) 2.06 0.92–4.61 1.44 0.60–3.43
Marked elevated (.80) 93 (8.8) 13 (29.5) 5.90*** 2.96–11.75 5.41*** 2.60–11.29
Alcohol use disorder (yes/no) 114 (9.1) 13 (27.1) 5.42*** 2.84–10.34 4.35*** 2.14–8.83
Antipsychotic drug use (yes/no) 743 (59.3) 21 (43.8) 0.58 0.33–1.03 0.65 0.35–1.22
HBsAg (yes/no)
+++ 180 (18.3) 11 (26.2) 1.48 0.74–2.95 1.61 0.78–3.33
HBsAg: hepatitis B surface antigen;
aAdjusted for gender, age, hepatitis B surface antigen, antipsychotic drug use, and alcohol use disorder.
*p,0.05,
**p,0.01,
***p,0.001.
+missing values: 187,
++missing values: 194,
+++missing values: 273.
doi:10.1371/journal.pone.0029325.t004
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mildly and markedly elevated levels were 2.08 (95% CI, 0.82–
5.29, p=0.125) and 4.29 (95% CI, 1.72–10.69, p=0.002),
respectively.
Discussion
To our knowledge, this is the first study to identify the factors
associated with natural death among patients with methamphet-
amine dependence. We utilized a national identification system
that allowed effective tracking of mortality, except for rare
instances of people who migrated outside of the country during
the study period (about 2 of 1,000 population per year nationwide
[14]). Additionally, through a two-phase study design, we explored
the potential factors associated with natural death by means of a
nested case-control study and then confirmed the results through a
cohort study, which diminished the potential for selection bias.
This study provides a clear temporal sequence for investigating the
factors associated with natural death, which are critical to the
development of intervention strategies.
One of the important findings in this study was the
confirmation of the convincing association between AST and
ALT elevations and natural death. It provides support for a dose-
dependent relationship in which the underlying causes of high
AST could induce natural death. As for ALT, the data are
similar despite no significantly higher risk in those with mildly
abnormal ALT. Thus, both markers, as identified surrogate
markers, should be monitored in routine clinical examinations.
ALT is an enzyme more specific to liver damage. AST is similar
to ALT in that it is another enzyme associated with liver
parenchymal cells, but AST is also present in several other organ
systems, including cardiac muscle, skeletal muscle, kidneys, and
brain tissue [9]. This could mean AST, an enzyme indicating the
extent of harm to multiple organs systems (not limited to the
liver), is more sensitive than ALT as a predictor of the risk of
natural death.
Furthermore, the presence of strong residual effects (comorbid
alcoholism-adjusted) of AST/ALT elevations on natural deaths in
modeling statistics indicate that methamphetamine could have a
direct effect on the organ systems leading to death that is
attributed to illness in that organ system. The possible mechanisms
of methamphetamine toxicity in humans are difficult to determine
from experimental studies due to the illicit nature of metham-
phetamine and ethical constraints. However, the findings of
animal studies could help shed light on the harm of methamphet-
amine in humans. In rats, a study [15] investigated transaminase
activity in response to persistent 4-week administration of
amphetamine sulfate and revealed marked increases in serum
AST levels and mild increases in ALT levels. In dogs,
amphetamine increased plasma levels of both AST and ALT
[16], although a later study reported significant increases in AST
level, but no change in ALT level [17]. The increase in plasma
AST and ALT levels could reflect an effect of amphetamine on the
plasma membrane of cells in the organ [16].
The literature depicts several comorbid illnesses [3,7] metham-
phetamine users are likely to have that could contribute to death.
In our study, comorbid alcohol use disorder was associated
significantly with natural death in the AST and ALT models. The
relationship between methamphetamine and natural death could
be partially mediated by alcoholism. Our results suggest that
methamphetamine dependents with comorbid alcoholism com-
prise a high-risk group for natural death; thus, effective treatment
of alcoholism is warranted.
While the factor of comorbid alcohol use disorder was extracted
in the phase I nested case-control study, we confirmed the
increasing risk of alcohol use disorder for natural death in the
phase II cohort study comprising 1254 patients. Additionally, in
the phase II study, we conducted survival analyses for the variables
Figure 1. Stacked bar chart of the distributions (%) of aspartate (AST) and alanine (ALT) aminotransferase levels at the latest
hospital admission among the cases of natural death and the remaining non-cases of the original cohort, respectively.
doi:10.1371/journal.pone.0029325.g001
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decreased the possibility of selection bias.
The duration of methamphetamine use, intriguingly, was not
associated with natural death in this study. In light of a review [8]
reporting that the risk of cardiovascular pathology was unlikely to
be limited to the duration of methamphetamine use, we suggest
that the patients with markedly elevated AST/ALT levels could be
individuals who are specifically vulnerable to methamphetamine
damage. Additionally, a prior study reported that methamphet-
amine toxicity is increased with comorbid alcohol use, thus, the
two could have a synergistic effect when used together [18].
Nonetheless, we could not precisely evaluate the effect of the
interaction between duration of methamphetamine use and
alcohol use disorder on the risk of natural death due to the
unavailability of information regarding the exact cumulative years
of exposure to methamphetamine between the index admission
and natural death. Further research is needed to clarify whether
methamphetamine and alcohol use disorder have a synergistic
effect on the risk of natural death.
The administration of antipsychotic drugs was identified as a
potential protective factor for natural death in the phase I study,
but it was not confirmed with a significant association in the phase
II cohort study. This is an interesting issue for future work.
Methamphetamine users are a high-risk group for hepatitis C
virus comorbidity, which is associated with elevations of AST and
ALT [7]. In this study, antibody against hepatitis C virus was
included as a routine laboratory item in only part of the study
period. The partially available data for hepatitis C antibody in the
phase I study revealed no statistical significance between case (1/4,
25%) and control subjects (4/24, 16.7%) (p=0.69). Further study
is needed to investigate the contribution of hepatitis C virus to
natural deaths of methamphetamine-dependent subjects.
The limitations of this study should be considered when
interpreting the results. First, this study did not have post-
discharge information, in particular the uncertainty regarding
methamphetamine exposure and potential confounders or medi-
ators of the relationship between methamphetamine and natural
death (e.g., poor nutrition, other exposures). Future improvements
and challenges for this work include maintaining contact with the
methamphetamine-dependent patients. Second, this study inves-
tigated the association between methamphetamine use and natural
death – that is, deaths coded as physical illness-related, an
inherently heterogeneous category. Nonetheless, if we restricted
the outcome as those dying from cardiovascular disease (12 cases),
for example, and conducted the further analyses, the findings were
similar. In the AST model, the adjusted hazard ratios for the
mildly and markedly abnormal AST levels at latest admission in
association with natural death were 5.74 (p=0.013) and 8.40
(p=0.008) respectively. Fourth, several laboratory indices includ-
ing lactate dehydrogenase (LDH) and creatine phosphokinase
(CPK) were unmeasured in our clinical routine. Further research is
needed to clarify the association between these indices and natural
death in the specific population. Lastly, there were some missing
data for the identified variables, including AST, ALT, and
hepatitis B surface antigen. The further analyses revealed no
differences for the proportions of missing values in these variables
between the natural death cases and other subjects. Therefore, the
systematic missing data did not influence the estimates of this
study.
In conclusion, this study provides valuable insight into the
factors associated with natural death among patients with
methamphetamine dependence. AST and ALT are strong
surrogate markers associated with increased risk of natural death.
Based on these findings, we emphasize the necessity of intensive
follow-up for methamphetamine-dependent patients with elevated
AST/ALT levels and comorbid alcohol use disorder for
preventing excessive natural deaths.
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